» Articles » PMID: 19300194

Donor-derived Mesenchymal Stem Cells Suppress Alloreactivity of Kidney Transplant Patients

Overview
Journal Transplantation
Specialty General Surgery
Date 2009 Mar 21
PMID 19300194
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Human mesenchymal stem cells (MSC) have immunosuppressive capacities. Although their efficacy is currently studied in graft-versus-host disease, their effect on alloreactivity in solid organ transplant patients is unknown. In this study, the immunosuppressive effect of MSC on recipient anti-donor reactivity was examined before and after clinical kidney transplantation.

Methods: Anti-donor reactivity was established in pretransplant and posttransplant mixed lymphocyte reactions (MLR) of 14 living-kidney donor-recipient pairs. MSC from donors and third-party controls were added to the MLR in a ratio of 1:5.

Results: MSC were isolated from donor perirenal fat and showed multilineage differentiation potential and the capacity to inhibit lymphocyte proliferation. The immunosuppressive effect of MSC was dose dependent and mediated by cell-membrane contact and soluble factors, including interleukin-10 and indoleamine 2,3-dioxygenase.Donor-derived MSC significantly inhibited the recipient anti-donor reactivity before and 1 month after transplantation. This effect was independent of human leukocyte antigen background of MSC. Flow cytometric analysis showed that MSC inhibited the proliferation of CD4+ and CD8+ T-lymphocyte subsets in pretransplant and posttransplant donor-directed MLR, whereas MSC had no effect on B- or natural killer-cell proliferation.

Conclusion: Donor MSC significantly inhibited the proliferation of alloactivated recipient T cells before and after kidney transplantation. We believe these findings should encourage MSC-based intervention in clinical organ transplantation.

Citing Articles

Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy.

Fodor Duric L, Basic Jukic N, Vujicic B J Clin Med. 2024; 13(19).

PMID: 39407823 PMC: 11476955. DOI: 10.3390/jcm13195763.


Regulatory cell therapy for kidney transplantation and autoimmune kidney diseases.

Ho Q, Hester J, Issa F Pediatr Nephrol. 2024; 40(1):39-52.

PMID: 39278988 PMC: 11584488. DOI: 10.1007/s00467-024-06514-2.


Therapeutic potential of mesenchymal stem cells for cerebral small vessel disease.

Chen D, Huang J, Su S, Chen Q, Wu B Regen Ther. 2024; 25:377-386.

PMID: 38414558 PMC: 10899004. DOI: 10.1016/j.reth.2023.11.002.


Mesenchymal stem cells and natural killer cells interaction mechanisms and potential clinical applications.

Abbasi B, Shamsasenjan K, Ahmadi M, Beheshti S, Saleh M Stem Cell Res Ther. 2022; 13(1):97.

PMID: 35255980 PMC: 8900412. DOI: 10.1186/s13287-022-02777-4.


Ex Vivo Mesenchymal Stem Cell Therapy to Regenerate Machine Perfused Organs.

Bogensperger C, Hofmann J, Messner F, Resch T, Meszaros A, Cardini B Int J Mol Sci. 2021; 22(10).

PMID: 34063399 PMC: 8156338. DOI: 10.3390/ijms22105233.